Year All2024202320222021 Apr 16, 2024 Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy Mar 13, 2024 Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing Mar 11, 2024 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Mar 11, 2024 Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing Feb 05, 2024 Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments Jan 03, 2024 Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Apr 16, 2024 Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Mar 11, 2024 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Feb 05, 2024 Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments